Vanda Pharmaceuticals, Inc. (VNDA)
5.43
+0.09
(+1.69%)
USD |
NASDAQ |
Sep 04, 16:00
5.43
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals EPS Diluted (Quarterly) : -1.038 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.038 |
| March 31, 2026 | -0.8168 |
| December 31, 2025 | -2.389 |
| September 30, 2025 | -0.3822 |
| June 30, 2025 | -0.4612 |
| March 31, 2025 | -0.5039 |
| December 31, 2024 | -0.0842 |
| September 30, 2024 | -0.0914 |
| June 30, 2024 | -0.0776 |
| March 31, 2024 | -0.0718 |
| December 31, 2023 | -0.0417 |
| September 30, 2023 | 0.0024 |
| June 30, 2023 | 0.0264 |
| March 31, 2023 | 0.0566 |
| December 31, 2022 | 0.12 |
| September 30, 2022 | 0.0574 |
| June 30, 2022 | 0.0453 |
| March 31, 2022 | -0.1146 |
| December 31, 2021 | 0.1237 |
| September 30, 2021 | 0.1362 |
| June 30, 2021 | 0.1696 |
| March 31, 2021 | 0.1531 |
| December 31, 2020 | 0.1473 |
| September 30, 2020 | 0.1077 |
| June 30, 2020 | 0.1582 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0089 |
| December 31, 2019 | 0.0767 |
| September 30, 2019 | 1.841 |
| June 30, 2019 | 0.2112 |
| March 31, 2019 | -0.0116 |
| December 31, 2018 | 0.1876 |
| September 30, 2018 | 0.1311 |
| June 30, 2018 | 0.0855 |
| March 31, 2018 | 0.0636 |
| December 31, 2017 | -0.04 |
| September 30, 2017 | -0.10 |
| June 30, 2017 | -0.03 |
| March 31, 2017 | -0.1722 |
| December 31, 2016 | -0.01 |
| September 30, 2016 | -0.01 |
| June 30, 2016 | -0.11 |
| March 31, 2016 | -0.29 |
| December 31, 2015 | -0.35 |
| September 30, 2015 | -0.22 |
| June 30, 2015 | -0.13 |
| March 31, 2015 | -0.24 |
| December 31, 2014 | 1.77 |
| September 30, 2014 | -0.04 |
| June 30, 2014 | -0.64 |
| March 31, 2014 | -0.79 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Protagonist Therapeutics, Inc. | 2.293 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -62.51M |
| Revenue (Quarterly) | 50.53M |
| Total Expenses (Quarterly) | 113.04M |
| Enterprise Value | 180.97M |
| Gross Profit Margin (Quarterly) | 89.02% |
| Profit Margin (Quarterly) | -123.7% |
| Earnings Yield | -85.19% |
| Normalized Earnings Yield | -85.19 |